Drug Patents owned by Janssen Therap

1. List of Sirturo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498343 JANSSEN THERAP Mycobacterial inhibitors
Dec, 2026

(3 years from now)

US8546428 JANSSEN THERAP Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
Mar, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 9, 2026
New Patient Population (NPP) Aug 9, 2022

Drugs and Companies using BEDAQUILINE FUMARATE ingredient

Market Authorisation Date: 28 December, 2012

Treatment: Treatment of pulmonary multi-drug resistant tuberculosis


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic